#4 - Exelixis (NASDAQ:EXEL)
Cancer research remains one of the key areas of emphasis for investors in the biotech sector. But the Biden administration’s call for a moonshot to find a cure is creating renewed interest. To that end, Exelixis, Inc. (NASDAQ: EXEL) recently saw its stock price move above the $20 range. But the stock looks like it has further to run.
The company's primary product, Cabometyx, is FDA approved as a treatment for several types of cancer, including renal and liver. And as biotech investors understand, you shouldn’t invest in this sector without looking at a company’s pipeline.
Exelixis doesn’t disappoint in that regard. The company has four candidates in Phase 3 clinical trials. It may still be over a year before any of these drugs are approved, if they ever do. But for companies investing in the company’s growth, this is encouraging.
Analysts give EXEL stock a Moderate Buy rating with a consensus forecast for 12% share price growth. However, earnings are projected to grow by 49%. If the company successfully meets that target, you should expect analysts to review their price targets.
About Exelixis
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Read More - Current Price
- $33.29
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 10 Buy Ratings, 7 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $32.44 (2.6% Downside)
